Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.

Pelcovits, Ari; Barth, Peter; Reagan, John L; Olszewski, Adam J; Rosati, Vallerie; Wood, Roxanne; Sturtevant, Ashlee; Winer, Eric S

Pelcovits, Ari; Barth, Peter; Reagan, John L; Olszewski, Adam J; Rosati, Vallerie; Wood, Roxanne; Sturtevant, Ashlee; Winer, Eric S.

Afiliação

Pelcovits A; Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.
Barth P; Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.
Reagan JL; Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.
Olszewski AJ; Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.
Rosati V; Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.
Wood R; Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.
Sturtevant A; Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.
Winer ES; Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.

Oncologist ; 28(5): 462-e303, 2023 05 08.

Article em En | MEDLINE | ID: mdl-36942937

Assuntos

Mieloma Múltiplo; Humanos; Mieloma Múltiplo/tratamento farmacológico; Universidades; Resultado do Tratamento; Dexametasona/uso terapêutico; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Ciclofosfamida/uso terapêutico

Palavras-chave

cyclophosphamide; ixazomib; metronomic dosing; multiple myeloma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google